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ABSTRACT 
Febrile neutropenia is a serious and potentially fatal complication in oncology patients 
treated with chemotherapy, with a mortality rate of 5-20%. The severity and the duration of 
neutropenia depend on type of malignancy, as well as the chemotherapy schema. Treatment with 
aggressive chemotherapy regimens has an increased risk of neutropenia associated with 
consequent bacterial or fungal infections. Fever in neutropenic patients is usually associated with 
bacterial infections, while fungal infections occur more frequently in a severe and prolonged 
neutropenia context with a mortality rate of 55%. 
 In hematological malignancies, neutropenia induced by the myelosuppressive effect of 
chemotherapy has not been associated with the same infectious risk, varying with neutropenia 
progression and type of treatment. In Hodgkin Lymphoma, an indolent type of pathology, 
treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy has been 
associated with significant neutropenia although with frail association with infection when 
compared with other therapeutic regimens. In Acute Myeloid Leukemia, neutropenia caused by 
induction chemotherapy with cytarabine and idarubicin is significant, with high bacterial infection 
risk. It is not so well understood in what it concerns fungal infections. 
Considering the high mortality risk in patients with febrile neutropenia, prompt 
prophylactic or acute treatment has been shown critical in mortality reduction. However, there has 
been an increased mortality in neutropenic patients caused by infections with drug resistant 
microorganisms.  Differences described in the infectious profile of neutropenia in hematological 
diseases raise the question of whether an aggressive antimicrobial therapeutic approach is needed 
for all hematological malignancies. The potential risk of developing microbe resistant strains in 
subsequent infection in these patients, and true cost-benefit of center specific antimicrobial 
therapeutic protocols, should lead to a more individualized and efficient medical approach. 
The objective of this bibliographic review is to analyze the different studies regarding 
neutropenia in hematological malignancies, having as paradigms: ABVD-treated Hodgkin 
Lymphoma, whose neutropenia is frequent and severe but seems to be rarely associated with 
infection and Acute Myeloid Leukemia in remission induction chemotherapy, usually associated 
with infections in the context of prolonged neutropenia. 
A reflection about the true infectious risk and the use of wide-spectrum antibiotics should 
be brought up by this literature review. 
Keywords: neutropenia, chemotherapy, febrile neutropenia, prophylaxis, infection, 
hematological malignancies, Hodgkin Lymphoma, Acute Myeloid Leukemia.  
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RESUMO 
A neutropenia febril é uma complicação grave e potencialmente fatal em doentes 
oncológicos tratados com quimioterapia, com uma taxa de mortalidade de 5-20%. O grau e duração 
de uma neutropenia dependem do tipo de neoplasia e da quimioterapia utilizada. O tratamento 
com quimioterapia agressiva associa-se a um risco de neutropenia com potencial desenvolvimento 
de infeções bacterianas e fúngicas. O desenvolvimento de febre nos doentes neutropénicos está 
normalmente associada a infeções bacterianas, enquanto as infeções fúngicas ocorrem mais 
frequentemente no contexto de uma neutropenia grave e prolongada com uma mortalidade até 
55%. Nas neoplasias hematológicas, as neutropenias induzidas pelo efeito mielossupressor da 
quimioterapia não têm mostrado o mesmo risco infecioso, variando com a patologia, com a 
evolução da neutropenia e com o tipo de tratamento. No Linfoma de Hodgkin o tratamento com 
ABVD (adriamicina, bleomicina, vimblastina e dexametasona) tem sido associado a neutropenia 
importante, mas com fraca associação a infeção, quando comparado com outros esquemas 
terapêuticos. Na Leucemia Mieloide Aguda, as neutropenias que se desenvolvem com a 
quimioterapia de indução com idarrubicina e citarabina são significativas e com elevado risco 
infecioso bacteriano. Não é, contudo, tão claro no que diz respeito às infeções fúngicas.  
Considerando a mortalidade significativa nos doentes com neutropenia febril, a instituição 
da profilaxia ou tratamento emergente tem-se mostrado crítica na redução da mortalidade. 
Contudo, verifica-se um aumento da mortalidade em doentes neutropénicos causada por infeções 
com micro-organismos resistentes. As diferenças que têm sido descritas no perfil infecioso das 
neutropenias nas diversas patologias hematológicas levam a questionar a verdadeira necessidade 
de uma abordagem terapêutica antimicrobiana agressiva para todas as neoplasias hematológicas.  
Os potenciais riscos de desenvolvimento de resistências microbianas em infeções 
subsequentes nestes doentes, e a relação custo-benefício das terapêuticas antimicrobianas 
protocoladas nos hospitais, devem fazer pensar numa abordagem médica mais individualizada e 
eficiente.  
O objetivo desta revisão bibliográfica é analisar os estudos existentes sobre as neutropenias 
nas neoplasias hematológicas, tendo como paradigmas: o Linfoma de Hodgkin tratado com ABVD, 
cuja neutropenia associada é frequente e profunda, mas raramente associada a infeção; e a 
Leucemia Mieloide Aguda em tratamento de indução, habitualmente associada a infeções no 
contexto de neutropenia prolongada. Pretende-se ainda, uma reflexão acerca do risco infecioso nas 
neutropenias e uso de antibioterapia de largo espetro. 
Palavras-chave: neutropenia, quimioterapia, neutropenia febril, profilaxia, infeção, 
neoplasias hematológicas, Linfoma de Hodgkin, Leucemia Mieloide Aguda.  
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ABBREVIATIONS 
A+AVD - Brentuximab-vedotin plus Doxorubicin (Adriamycin), Vinblastine and Dacarbazine  
ABVD - Doxorubicin (Adriamycin), Bleomycin, Vinblastine and Dacarbazine 
AML - Acute Myeloid Leukemia 
ANC - Absolut Neutrophil Count 
ARF - Acute Respiratory Failure 
ASCO - American Society of Clinical Oncology 
ASH - American Society of Hematology   
ASXL1 - Additional Sex Combs-Like 1 
BEACOPP - Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and 
Prednisone 
CD30 - Lymphoid transmembrane receptor of the tumor necrosis factor receptor superfamily 
CHOP - Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone 
CIN - Chemotherapy-induced neutropenia 
CISNE - Clinical Index of Stable Febrile Neutropenia 
COPD - Chronic Obstructive Pulmonary Disease 
CT - Chemotherapy 
DNA - Deoxyribonucleic Acid 
EBV - Epstein-Barr Virus 
ECIL - European Conference on Infections in Leukemia 
EORTC - European Organization for Research and Treatment of Cancer 
ESBL - Extended spectrum β-lactamase 
ESMO - European Society for Medical Oncology 
FDA - United States Food and Drug Administration 
FDG-PET - Fluoro-deoxyglucose positive emission tomography 
FLT3 - FMS-like tyrosine kinase 3 
FN - Febrile Neutropenia 
G-CSF - Granulocyte Colony-stimulating Factor 
HMA - Hypomethylating Agents 
HSCT - Hematopoietic Stem Cell Transplantation 
HiDAC - High Dose Cytarabine  
HIV - Human Immunodeficiency Virus 
HL - Hodgkin Lymphoma 
HLA - Human Leukocyte Antigen  
IDSA - Infectious Diseases Society of America  
IFD - Invasive Fungal Disease 
IIHS - International Immunocompromised Host Society 
Non-HL - Non-Hodgkin Lymphoma 
LDH - Lactate Dehydrogenase 
MASCC - Multinational Association for Supportive Care in Cancer  
MRSA - Methicillin-resistant Staphylococcus aureus 
NCCN - National Comprehensive Cancer Network 
TP53 - Tumor suppressor Protein p53  
USA - Unites States of America 
VRE - Vancomycin-resistant enterococci
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1. INTRODUCTION 
Over the last decades the overall survival of oncologic patients has suffered a remarkable 
progress. This relates in particular with increased development of both diagnostic and therapeutic 
options offered to these patients. Regardless of the important breakthrough in the field of 
biological treatments, chemotherapy (CT) continues to play a central role in neo-adjuvant, adjuvant 
and palliative care in oncology 1.  However, the majority of CT protocols induces suppression of 
both innate and adaptive immunity, neutropenia being an important deleterious consequence of 
this treatment and constituting a risk factor for infection in oncologic patients 2. In 1966, Bodey and 
coworkers have shown that adults with a reduction in numbers of neutrophils (neutropenia) 
following cytotoxic CT were in direct risk of serious infection, and that early aggressive treatment 
with broad spectrum antibiotics could contribute to a decrease in mortality rates 3,4. This clinical 
manifestation of neutropenia with fever was then on known as ‘febrile neutropenia’ (FN). Marked 
differences between cancer patients have been documented in their response to infection 5,6.  
The pathophysiology of infection following the administration of CT is complex. Deficiencies 
occur in both innate and adaptive immunity, with changes in cellular and non-cellular elements of 
the defense mechanisms against infection 7. Anatomical barriers are also compromised by the 
effects of chemo- and radiotherapy with disruption of the gut mucous membranes and the skin 
integrity with resultant mucositis and dermatitis, respectively. This, in turn, enables local tissue 
infection and colonization or bacteria dissemination into the blood stream 8.  
Although CT treatments have improved the overall survival in oncologic patients, it has 
been done at the expense of neutropenia development, with increased risk factor for susceptibility 
to bacterial/fungal infections. 
The objective of this study is to present a literature review about the subject neutropenia 
and infection in hematological malignancies, having as paradigms: ABVD-treated Hodgkin 
lymphoma (HL), whose neutropenia is frequent and severe but rarely associated with infection and 
Acute Myeloid Leukemia (AML) in remission induction CT, usually associated with infections in the 
context of prolonged neutropenia. With this revision, a reflection about the true infection risk in 
CT-induced neutropenia (CIN), the routine use of wide-spectrum antibiotics and potential 
treatment compromise, should be carried out.  
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2. METHODS 
In our research strategy and selection criteria for a systematic literature search, we used 
the Medline database (via PubMed) to search for English-language articles published in the last 15 
years (from January 2004 until June 2019). Some articles published before were also included 
because they were considered relevant to this subject. Keywords used in this search were, 
neutropenia, chemotherapy, febrile neutropenia, prophylaxis, infection, Hodgkin Lymphoma, 
Acute Myeloid Leukemia and hematological malignancies, using the following search strategies: 1. 
("neutropenia"[All Fields]  OR "febrile neutropenia"[All Fields]  OR “infection” [All Fields]) AND 
("Hodgkin lymphoma"[All Fields]  OR "Acute Myeloid Leukemia"[All Fields]  or "Hematological 
malignancies"[All Fields]); 2. ("chemotherapy"[All Fields] OR "prophylaxis"[All Fields]) AND 
("neutropenia"[All Fields] OR "febrile neutropenia"[All Fields] OR “infection”[All Fields]) AND 
("Hodgkin lymphoma"[All Fields] OR "Acute Myeloid Leukemia"[All Fields] OR "Hematological 
malignancies"[All Fields]). We reviewed all retrieved titles and abstracts for relevance, and further 
assessed full papers that we judged appropriate for inclusion in this work. From different keyword 
combination strategies, in total, 221 articles were used for this review. Case reports, low quality 
studies and conference meeting abstracts were excluded. 
 
3. FEBRILE NEUTROPENIA 
Febrile neutropenia (FN) is one of the most serious problems in patients with cancer who 
receive myelosuppressive CT, increasing infection risk that frequently requires hospitalization and 
treatment with broad-spectrum antibiotics 9-11. Patients who develop FN during CT treatment not 
only have increased rates of morbidity and mortality 10,12 and higher health care costs 13,14, but are 
also more likely to require reduction in chemotherapy dose intensity, or experience treatment 
delay or even treatment discontinuation, all of which can lead to reduced treatment response and 
lower survival 15-18. 
FN may represent the only sign of severe infection in cancer patients, since symptoms and 
signs of inflammation are typically attenuated due to a reduced absolute neutrophil count (ANC) 
19,20. The frequent need for indwelling central venous catheters in association with damage of the 
gastrointestinal mucosa caused by anticancer agents provides a portal of entry for pathogenic 
bacteria, predisposing patients to bacteremia 21. This fact, in association with an impaired host 
response to infection due to neutropenia and decreased cellular immunity secondary to intensive 
CT, leads to increased risk for severe infections in cancer patients. Despite recent improvements in 
managing FN, infections in the context of neutropenia continue to be associated with substantial 
mortality, which may reach values of approximately 10% in specialized centers 12,16. In patients who 
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develop septic shock, pneumonia or documented bacteremia, mortality exceeds 50% 22, despite 
prompt antibiotic initiation. 
Both fever and neutropenia definitions have not been consensual. Average normal body 
temperature of 37ºC has been proposed by Carl-Wunderlich in 1868, which considered values 
above 38ºC as fever 23.   The Infectious Diseases Society of America (IDSA), American Society of 
Clinical Oncology (ASCO), American Society of Hematology (ASH) and National Comprehensive 
Cancer Network (NCCN) define fever in a neutropenic patient as one individual temperature 
measurement ³38.3 ºC or 38ºC for more than one hour 21.  The European Society for Medical 
Oncology (ESMO) defines FN as an oral temperature of >38.3°C or two consecutive readings of 
>38.0°C for 2 hours and an ANC of <500 cells/µL or expected to fall below 500 cells/µL 24. 
Neutropenia definition varies from institution to institution, but is usually defined as an ANC of 
<1500 or 1000 cells/µL. Severe neutropenia is usually defined as an ANC <500 cells/µL or an ANC 
that is expected to decrease to <500 cells/µL over the next 48 hours 24. Profound neutropenia is 
defined by an ANC <100 cells/µL. The risk of clinically important infection rises exponentially as the 
neutrophil count falls below 500 cells/µL and is higher in those with a prolonged duration of 
neutropenia (more than 7 days) 21.  
The severity of neutropenia, which directly influences the frequency of FN, is related to 
different CT characteristics, the intensity, the number of agents and respective doses, as well as the 
myelotoxic potential of each component. Nevertheless, the correlation between the type of CT and 
the risk of FN is far from being optimal because they do not take into account the factors linked to 
the type of malignancy and respective co-morbidities, which can influence the risk of developing 
FN despite the use of the same type of CT, as well as the risk of complications and death during an 
episode of FN 25. Different models tried to classify the common CT regimens according to the risk 
of FN as being low (<10%), intermediate (10%-20%) or high (>20%), but their predictive values are 
not very strong 15,26,27. 
 
3.1. Febrile neutropenic syndromes 
Studies involving patients with different tumors (lymphoma, breast, colon, lung, ovary and 
others) have shown that the risk of developing FN is maximal during the first cycle of CT, diminishing 
afterwards 28. In hematologic malignancies involving the bone marrow, recovery of normal 
hematopoiesis is slower after first cycle of treatment and hence neutropenia is more prolonged, 
and the risk of FN is more pronounced. 
A number of neutropenic fever syndromes have been described 29. Similar to the immune 
reconstitution inflammatory syndrome, that can follow the initiation of antiretroviral therapy in 
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patients with Human immunodeficiency virus (HIV) infection, the myeloid reconstitution syndrome 
is a neutropenic syndrome defined by fever and a new inflammatory focus or progression of a 
preexisting inflammatory focus in temporal relationship to neutrophil recovery from aplasia.  
The International Immunocompromised Host Society (IIHS) has classified initial neutropenic 
fever syndromes into the following three categories 30:  
1) Microbiologically documented infection – Neutropenic fever with a clinical focus of 
infection and an associated pathogen;  
2) Clinically documented infection – Neutropenic fever with a clinical focus (e.g., cellulitis, 
pneumonia) but without the isolation of an associated pathogen; 
 3) Unexplained fever – Neutropenic fever with neither a clinical focus of infection nor an 
identified pathogen.  
 
3.2. Risk Stratification  
 Risk stratification allows for a guided orientation of both medical and therapeutic approach 
febrile neutropenic patients. Clinical evaluation focuses on assessing the risk of serious 
complications, including the need for hospital admission, intravenous antibiotics, and prolonged 
hospitalization 21,24,31.  
 Risk factors predictive for developing FN can be divided in three categories: patient-related 
(history of prior FN, age >65 years, female gender, obesity, cardiovascular disease, poor 
performance and nutritional status), disease-related (high levels of lactate-dehydrogenase [LDH] in 
lymphoproliferative disease, bone marrow failure due to tumor invasion and advanced stage of 
oncologic disease) and treatment-related (mucositis, high-dose CT regimens without leucocyte 
growth factor administration, no use of antibiotic prophylaxis or granulocyte colony-stimulating 
factor [G-CSF]) 32-34.  
Overall, the risk of serious medical complications in febrile neutropenic patients with one 
or more co-morbidities is significantly increased, which in turn will contribute in deciding whether 
a CT-treated patient should receive primary antibiotic prophylaxis to decrease the potential risk of 
FN 24.  
Considering the different risk stratification systems, several international organizations 
(ASCO, IDSA, NCCN and ESMO) developed specific guidelines for FN 21,24,31,35. Validated scoring 
systems used to estimate the risk for medical complications include the Talcott rules, the 
Multinational Association for Supportive Care in Cancer (MASCC) score, and the Clinical Index of 
Stable Febrile Neutropenia (CISNE) score 36-38. Generally, a low-risk patient for serious complications 
is defined as a neutropenic patient whose neutropenia (ANC <500 cells/µL) is expected to last less 
than 7 days and that does not have any active co-morbidities, or evidence of significant hepatic or 
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renal dysfunction and have an MASCC score ≥21 or a CISNE score of 0 at the time of assessment. 
Most patients receiving CT for solid tumors are considered to be of low risk for complications 
requiring hospitalization. This group of patients has been target at randomized studies which 
demonstrated their low risk for serious medical complications 21,24,31,39. High-risk for serious 
complications is considered in neutropenic patients whose neutropenia (ANC <500 cells/µL) is 
expected to last for more than 7 days, present ongoing co-morbidities, liver or renal dysfunction, 
and have a MASCC score <21 or a CISNE score of ≥2 at the time of assessment 37,38,40 requiring 
immediate hospitalization and urgent evaluation.  
Risk stratification in a febrile neutropenic patient depends significantly on the underlying 
malignancy. The majority of hematological malignancies automatically characterize a high-risk 
patient 29,41. Patients receiving CT for solid tumors will generally have neutropenia that lasts less 
than 7 days, and only 5% to 30% will have FN, with the highest rates occurring during the first cycle 
of treatment. Conversely, patients undergoing hematopoietic stem-cell transplantation (HSCT) with 
conditioning therapy or receiving CT for hematologic malignancies may have neutropenia lasting 
longer than 14 days. Consequently, more than 80% of patients receiving CT for leukemia or 
undergoing allogeneic HSCT will experience at least one episode of FN 15,21,42,43. 
Some experts have defined high-risk patients as those expected to have profound 
prolonged neutropenia (ANC ≤100 cells/µL for more than 7 days) based on experience that such 
patients are most likely to have life-threatening complications, tending to occur in the pre-
engraftment phase of HSCT (particularly allogeneic) and in patients undergoing induction CT for 
acute leukemia 21,35. However, formal studies that clearly differentiate between patients with an 
ANC <500 cells/µL of patients with ANC ≤100 cells/µL are lacking 44.  
 
3.3. Epidemiology 
The type of underlying neoplasia, hematological malignancy or solid tumor, does not 
significantly influence the incidence of complications or deaths in FN 25. However, the presence of 
bacteremia notably increases morbidity and mortality. Bacteremia is not easy to predict on a clinical 
basis at the time of onset of fever, although manifestations such as high temperature, hypotension 
and thrombocytopenia are possible clues for it. The presence of a focal infection and specific local 
complications (e.g., pneumonia or cellulitis) increases the risk of dying during an episode of FN; 
probably as a substitute of bacteremia 45.  
The Gram-negative Enterobacteriaceae (Escherichia coli, Klebsiella spp, Enterobacter spp) 
and Pseudomonas aeruginosa, are the most common pathogens causing bloodstream infections in 
neutropenic patients with cancer. Lately, Gram-positive bacteria have become more prevalent, 
such as coagulase-negative staphylococci and viridans group streptococci. Nevertheless, due to the 
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high morbidity and mortality associated with Gram-negative sepsis, empiric therapy for FN should 
target these organisms specifically. An increase in antibiotic-resistant strains has been described, 
such as extended spectrum β-lactamase (ESBL)-producing Gram-negative bacteria, vancomycin-
resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) 46. The presence 
of Gram-negative bacteremia has a high mortality rate (70%) in neutropenic patients who did not 
receive empiric antibiotics 47,48. In contrast, the overall mortality rate in patients with FN treated 
with empiric antibiotics is just 4% to 20%. Increased mortality was seen in patients presenting co-
morbidities, documented Gram-negative rod bacteremia, and/or tissue-invasive infections such as 
pneumonia 12. Throughout decades the optimal treatment for FN was based in the prompt 
administration of broad-spectrum antibiotics to all neutropenic patients with fever, although with 
time, patients with FN start constituting a heterogeneous population and usually only a minority 
develops major serious complications 49. 
Candida spp and Aspergillus spp account for most invasive fungal infections during 
neutropenia. The former is acquired through gastrointestinal tract colonization and translocation 
across damaged intestinal epithelial surface. The latter are acquired by inhalation of airborne 
spores into the upper and lower respiratory tract followed by germination and invasive hyphal 
growth 25. Increasing numbers of infections with fluconazole-resistant Candida strains (e.g., 
Candida krusei and Candida glabrata) have also been reported 50. Fungal infections are common in 
high-risk patients with FN but are uncommon in low-risk patients. The risk for invasive fungal 
infections increases with the duration and severity of neutropenia, prolonged antibiotic use, and 
number of CT cycles. Fungi are rarely the cause of the first febrile episode in neutropenic patients. 
Invasive fungal infections are usually identified as a cause of persistent or recurrent fever beyond 
the first week of neutropenia. However, fungal infections can occasionally present early or even 
prior to initial CT 51. In an autopsy study of patients who died after prolonged FN between 1966 and 
1975, 69% of patients had evidence of invasive fungal infections 52. It is important to note that this 
study was done before either antifungal prophylaxis or early diagnosis and treatment of invasive 
fungal infections was routine.  
The underlying malignancy and the cumulative treatment also influence the risk and 
spectrum of infection. Patients with refractory disease who have received multiple lines of CT and 
more prolonged neutropenia are typically at higher risk for infectious complications compared with 
patients at earlier stages of their treatment course 46.  
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3.4. Prophylaxis and Treatment 
  3.4.1 Chemoprophylaxis  
Antibiotics have been used for the prevention of episodes of FN in CT treated patients. A 
Cochrane meta-analysis published in 2005 recommended the use of ciprofloxacin or levofloxacin in 
cancer patients undergoing intensive CT 53. This approach has been successful but resistant strains 
started to emerge, limiting its efficacy. Since the 1990s, fluoroquinolones have been used 
extensively for chemoprophylaxis. Several studies have shown that fluoroquinolones reduce the 
incidence of infection and the infection-related mortality. However, with the emergence of 
quinolone-resistant strains, prophylaxis is rendered useless. Additionally, these strains 
compromised the use of fluoroquinolones as a therapeutic option in low-risk patients. Recent 
guidelines from the European Organisation for Research and Treatment of Cancer (EORTC) and 
American Society of Clinical Oncology (ASCO) recommend that clinicians limit the use of antibiotic 
prophylaxis to patients at high risk for FN 24. 
 
  3.4.2. Prophylaxis with Granulocyte Colony-Stimulating Factor 
Primary prophylaxis with G-CSF, i.e. G-CSF administered immediately after cycle 1 of CT, 
reduces the risk of FN by at least 50% in patients with solid tumors without significantly affecting 
tumor response or overall survival 28,45,54.  
Prophylactic G-CSF is recommended to be administered when the risk of FN is >20% for all 
cycles of treatment 55. For patients with an intermediate risk (10%–20%), it is important to assess 
clinical factors that increase the frequency or risk of FN, such as patient age co-morbidities and CT 
regimen 34,55,56. G-CSF can also be considered in patients with reduced bone marrow reserve due to 
extensive radiotherapy or neutropenia in the context of HIV infection 24. Recent studies confirmed 
a significant success in FN chemoprevention when using primary prophylaxis with filgrastim or 
pegfilgrastim 57,58. 
In most CT regimens used for common tumors, the risk of FN is maximal during the first 
course. Therefore, it is reasonable to recommend primary prophylaxis for the patients at risk rather 
than to use secondary prophylaxis as an alternative. Secondary prophylaxis (i.e. G-CSF given for a 
course of CT following a course with FN) is indicated if a significant dose reduction or delay of CT 
will compromise the treatment with a curative intent. There are few complications associated with 
G-CSF administration, the most common adverse effect is minor or moderate bone pain that can 
usually be handled with standard analgesics 24.  
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3.4.3. Treatment 
The management of FN requires urgent evaluation and medical attention with prompt 
administration of antibiotics. Empiric antibiotics are standard of care and significantly reduce 
morbidity and mortality in patients with cancer with FN 16. 
Patients with a high MASCC score and thus considered to be low risk, which are planned to 
be treated as outpatients, are usually given a dose of intravenous antibiotics after blood cultures 
were obtained. Then they may be treated with oral antibiotics 35,59. However, patients who are 
already receiving an oral fluoroquinolone as prophylaxis are not candidates for treatment with oral 
agents 31.  
Patients with fever and neutropenia who do not meet the low-risk MASCC criteria (score 
<21) are considered to be at high risk for complications during their course of neutropenia 31. 
Although duration of neutropenia is not included as a risk factor in the MASCC scoring system, it is 
of practice to admit all patients who are receiving CT, especially for acute myelogenous leukemia, 
or HSCT, and are expected to have more than a week of low ANC (<500 cells/µL). High-risk patients 
should be admitted to the hospital for evaluation and treatment of potential infection with a broad-
spectrum parenteral antibiotic with antipseudomonal activity 60.  
The following two management strategies have been outlined for the treatment of these 
patients: escalation and de-escalation 61. The de-escalation approach includes initial multiagent 
therapy that includes coverage for multidrug-resistant Gram-negative and Gram-positive bacteria 
(e.g., carbapenem in combination with an aminoglycoside and glycopeptide). Once the patient is 
stable or a bacterial pathogen is identified, treatment can be de-escalated to a narrower targeted 
therapy. Alternatively, patients with FN who are stable at presentation are typically treated with 
the escalation approach with ß-lactam monotherapy initially with addition of agents if indicated on 
the basis of culture data or clinical deterioration 61. 
The choice of monotherapy should be guided by previous infections and susceptibility 
patterns as well as institutional antibiograms 21,35. Patients with abdominal symptoms such as 
abdominal pain or diarrhea may also need anaerobic coverage with the preferential use of 
piperacillin-tazobactam as initial empiric therapy or the addition of metronidazole to cefepime.  
Although the antipseudomonal carbapenems have excellent anti-anaerobic activity, they 
are best reserved for use in treating complicated infections with drug-resistant organisms. 
Depending on site antibiogram profiles showing carbapenem coverage of most Gram-negative 
pathogens, carbapenems may be a good choice for neutropenic patients presenting with sepsis. 
Carbapenems are not recommended for routine coverage in uncomplicated, stable patients.  
Although Gram-positive bacteremia have become more common in the past 30 years, they 
rarely cause mortality in patients with FN, with the exception of viridans group streptococci. 
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Therefore, for stable patients without sepsis, pneumonia, mucositis, or evidence of line infection, 
there is no benefit of empirically adding vancomycin to the initial empiric regimen used for 
management of neutropenic fever 62,63. Several clinical practice guidelines exist to help with 
management of FN 21,24,64. 
Patients with neutropenic fever should be examined daily with attention to fever curve and 
new signs or symptoms. Therapy should be broadened to include coverage against resistant Gram-
negative, Gram-positive bacteria, anaerobes as well as the Candida fungus if the patient is septic. 
In patients who are stable but have ongoing fever despite more than 3-4 days of treatment 
with broad-spectrum antibiotics without an identified source, there is no need to broaden antibiotic 
therapy. Fever alone in an otherwise stable patient is not an indication to add or change 
antimicrobials. However, additional work-up may be indicated in patients with new or persistent 
fever during neutropenia.  
High-risk patients with hematologic malignancies who are anticipated to have neutropenia 
for more than 7 days should be closely evaluated for invasive fungal disease (IFD). Fungal markers 
including galactomannan and 1,3-ß-D-glucan can be sent for evaluation, but sensitivities of these 
two tests are only 49% to 80% and 40% to 90%, respectively 65-67. Both markers are usually negative 
in the setting of mucormycosis. Therefore, empiric antifungal therapy should also be a 
consideration, especially in patients with acute leukemia, patients receiving allogeneic HSCT, or 
patients receiving high-dose corticosteroids who are at high risk for mold infections.  
Practices vary among centers and in the guidelines if no infectious etiology is identified. The 
European Conference on Infections in Leukemia (ECIL) guidelines suggests stopping broad-
spectrum antibiotic therapy and/or resuming prophylaxis. Conversely, the IDSA and NCCN favor the 
continuation of broad-spectrum therapy until recovery of neutrophils. However, in a recent 
multicenter study, patients with hematologic malignancies with FN and negative blood cultures 
were randomly assigned to either continuation of empiric antibiotics or cessation of antibiotics 
after being afebrile for 72 hours. Cumulative days of antibiotic therapy were lower in the group 
with early de-escalation, and adverse events, including recurrent fevers and infection, were similar 
between the two groups 39, suggesting that cessation of antibiotics before neutrophil recovery in 
stable afebrile patients without an identified infection may be a reasonable approach.  
 
4. MALIGNANT HEMATOLOGICAL DISEASES 
4.1. Hodgkin Lymphoma 
Hodgkin lymphoma (HL) incidence in Europe is 2.3 cases per 100 000 inhabitants per year 68. The 
disease has a bimodal distribution with an increased incidence in young adults as well as in patients 
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with 55 years and older 69. Factors shown to be associated with HL include familial factors, viral 
exposures, and immune suppression 69.  
While familial factors may suggest a genetic cause for this disease, research also suggests 
that immune response to infection may play a role in the pathogenesis of HL 70-72. It is known that 
after an episode of infectious mononucleosis, although small, there is a significantly increased risk 
of developing Epstein-Barr virus (EBV)-positive HL 70,73. HIV infected patients also have a significantly 
increased risk of HL when compared to the general population 72. In general, HL in 
immunocompromised patients, including those who are HIV positive, is associated with advanced 
stage HL at presentation, unusual sites of disease, and a poorer outcome after initial therapy 74,75. 
However, some childhood infections, such as, chickenpox, measles, mumps, rubella, and pertussis, 
are in turn, possibly protective and negatively associated with the risk of HL 71. 
Over the last decades, advances in radiation therapy and the addition of combination CT, 
have significantly increased the cure rate of HL patients, about 80% of all newly diagnosed patients 
younger than 60 years are likely to be cured of their disease 76.  
 
4.1.1. Diagnosis and Staging 
At the time of diagnosis, the majority of patients with HL present with supradiaphragmatic 
lymphadenopathy, commonly cervical, anterior mediastinal, supraclavicular, and axillary lymph 
node involvement 77,78. Approximately 30% of patients with advanced disease present systemic 
symptoms like fever, night sweats, and weight loss 79.  
The diagnosis of HL should be confirmed histologically. An excisional biopsy of the involved 
lymph node is preferred to establish a definitive diagnosis since the architecture of the lymph node 
is extremely important for an accurate diagnosis 80. HL is a unique malignancy in that the tumor 
cells constitute the minority of the cellular population and an inadequate biopsy may fail to include 
characteristic malignant Reed-Sternberg cells, which are of follicular B-cell origin, within the 
appropriate cellular environment of normal reactive lymphocytes, eosinophils, and histiocytes 81,82.  
HL is composed of two distinct disease entities; the more commonly diagnosed classical HL 
and the rare nodular lymphocyte predominant HL 83.  
Staging is carried out according to the Ann Arbor classification in consideration of defined 
clinical risk factors. After completion of staging, patients are allocated to one of three categories 
(limited, intermediate and advanced stages) critical for the selection of the appropriate therapy 68.  
Fluoro-deoxyglucose positive emission tomography (FDG-PET) scanning has emerged as an 
important tool in the staging of patients with HL in that it significantly adds to the information 
obtained using other standard radiographic methods 84-86.  
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4.2. Acute Myeloid Leukemia 
AML is the most common acute type of leukemia in adults, with an European incidence of 
5 to 8 cases per 100 000 individuals per year, increasing with age reaching 15 to 25 case per 100 000 
inhabitants per year in the population aged over 70 years, with a median age at diagnosis of 68 
years 87,88. Several genetic and environmental risk factors have been identified that predispose 
individuals to the development of AML 89. History of antecedent hematological disorders, including 
the myelodysplastic syndromes or myeloproliferative neoplasms, is also associated with a 
substantially increased likelihood of progression of AML 90,91.  
AML is a malignant disorder of haemopoietic stem cells characterized by clonal expansion 
of abnormally differentiated blasts of myeloid lineage. Proliferation of the immature myeloid cells 
leads to accumulation of immature progenitors (blasts) with impairment of normal hematopoiesis, 
leading to severe infections, anemia, and hemorrhage 89.  
Prompt diagnosis and initiation of AML directed therapy is imperative, especially when 
rapid proliferation of malignant blasts is accompanied by tumor lysis syndrome or disseminated 
intravascular coagulation, both of which can be rapidly fatal without aggressive supportive 
management and treatment of the underlying AML 92.  
AML is characterized by several recurrent mutations that affect disease biology and 
phenotype, response to therapy, and risk of subsequent relapse 93.  Advances have been made in 
understanding the genomic diversity of AML and how these various mutations interact to affect 
disease phenotype, prognosis and serve as potential targets for AML directed therapies 94-96.  
 
4.2.1. Diagnosis and Risk Stratification 
A diagnosis of AML requires identification of 20% or more myeloid blasts with 
morphological assessment of the peripheral blood or bone marrow 97. In addition, 
immunophenotyping by flow cytometry is used at the time of diagnosis to confirm the blast lineage 
and to help in further categorization of AML subtype 98. The 2016 WHO update recognized AML 
subgroups defined by the presence of recurrent genetic alterations, including balanced 
translocations, gene fusions, or single molecular mutations 97.   Additional genomic testing for FMS-
like tyrosine kinase 3 (FLT3), TP53, and additional Sex Combs-Like 1 (ASXL1) should also be done, 
considering their prognostic importance 99.  
The outcome of AML is heterogeneous, with both patient-related and disease-related 
factors contributing to an individual probability of achieving response to therapy and overall 
survival 89.  
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5. FEBRILE NEUTROPENIA IN HODGKIN LYMPHOMA COMPARED WITH 
ACUTE MYELOID LEUKEMIA 
The prevalence of hematologic malignancies has been increasing in developed countries, 
due to earlier diagnosis and improved treatment efficacy and patient care 100,101. The treatment of 
hematologic malignancies is based on a wide range of therapeutic options: CT, small molecules, or 
antibodies, which are often associated with toxic side effects ranging from nausea and vomiting to 
diarrhea and mucositis and to life-threatening myelosuppression 102.  
FN represents a life-threatening complication in hematological malignancies. Although its 
etiology is most often due to infections, FN of other origins, such as tumor-related fever and non-
infectious inflammation, should be excluded 103. CT-induced leukopenia stimulates endogenous 
cytokines, including interleukin-6 and tumor necrosis factor which can result in fever, even in the 
absence of infection 9.  
Tumor-associated fever is common in both hematological and solid-tumor malignancies, 
including HL and non-HL, AML, soft-tissue sarcoma, and renal cell carcinoma 104,105.  
Pel-Ebstein fever, is a non-infectious fever associated with HL and presents a cyclical 
pattern of several days of fever followed by afebrile episodes of 1 to 2 weeks 106. Moreover, in 
presence of neutropenia, tumor-associated fever is commonly found in acute leukemias attributed 
to the general hypermetabolic condition caused by the disease 107. No clinical features are 
consistently present to distinguish different causes of fever and therefore, tumor-associated fever 
is a diagnosis of exclusion 108-110. 
The central concern in a patient with FN is the risk of infection 12 and the incidence of 
infections appears to be dependent on the type of hematological malignancy and on the employed 
CT regimen 111. Congenital neutropenia studies also relate the duration and degree of neutropenia 
with the infection risk in patients with severe chronic neutropenia 112. 
 
5.1. Neutropenia and Neutropenic Complications during Chemotherapy for 
Hodgkin Lymphoma  
The introduction of multi-agent CT regimens have changed the outcome of HL. The 
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, 
prednisone) dose-intensive regimen, developed by the German Hodgkin's Lymphoma Study Group 
(GHSG), is used in some countries for advanced-stage HL 113-115. Although having high efficacy, 
BEACOPP is a highly myelotoxic regimen, with a FN incidence of >20% and is associated with greater 
risk of development of secondary malignancies 116-121. Therefore, it is reserved to young patients 
with a good performance status 122.  
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Combination therapy with doxorubicin (adriamycin), bleomycin, vinblastine and 
dacarbazine (ABVD) is, however, the standard CT regimen for patients with HL 123-125. HL is 
exquisitely responsive to ABVD CT, which results in a high cure rate. In order to achieve maximum 
benefit from this CT, it is important to maintain optimal dose intensity. Severe neutropenia is a 
well-recognized complication of this regimen, which in theory could lead to an increased risk of 
morbidity and mortality from infectious complications 126. For HL, retrospective data suggested that 
the incidence of FN with neutropenic sepsis, and death in patients receiving ABVD CT is low (<1%), 
although the proportion of patients with HL in these retrospective studies is small, and full details 
of the delivered CT were not described 126-129. 
Available evidence suggested that, although severe neutropenia is a common occurrence 
with ABVD therapy, FN and other related infectious complications are rare in this context 
118,120,123,130,131.  
Myelosuppression, in particular neutropenia, is common during ABVD treatment 124 and 
the effect of ABVD-related neutropenia and neutropenic complications on CT delivery in patients 
with HL, are poorly documented 124,126. 
In 2010, Schwenkglenks and colleagues presented a subgroup analysis of HL patients, to 
assess the effects of neutropenic complications on the delivery of ABVD CT. Infection was 
considered as FN when ANC was <1000 cells/µL in combination with fever above 38°C. The authors 
also characterized the incidence of CIN and FN in patients with HL undergoing ABVD. The results 
showed that CIN was substantial, with an incidence of 32% and 43% for an ANC <1000 cells/µL and 
<500 cells/µL, respectively. FN incidence in this small sample size was 11%, with 9% of HL patients 
experiencing FN in the first cycle of ABVD CT.  Despite the low rate of FN, treatment dose delays 
and dose reductions were frequent, resulting in suboptimal delivery of CT in approximately one 
fifth of patients with afebrile CIN.  Use of primary G-CSF prophylaxis appeared to reduce CT-induced 
neutropenia rates 132.  
In several randomized controlled trials including HL patients treated with ABVD and 
BEACOPP, the incidence of severe neutropenic events, including overall risk of FN has been 
assessed 117,118,120,133-135. Overall, these studies show a high rate of severe neutropenia (35%) 
induced by ABVD regimens with a FN median incidence of only 7%. This data suggests a low 
correlation between the level of neutropenia and the risk of infection in ABVD treated patients. 
Patients can safely proceed with ABVD CT in the presence of severe neutropenia, without 
other therapeutic interventions. Several ongoing multicenter and international trials in HL currently 
utilize full-dose ABVD without modifications for neutropenia. These prospective trials should 
confirm or refute the findings of the retrospective analyses described above 126,127,129.  
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In order to balance conflicting priorities of maintaining dose intensity while preventing 
neutropenia-related complications, physicians use different strategies, such as dose modifications, 
G-CSF support and antibiotic prophylaxis 136.  
Some of the greatest evidence of antimicrobial prophylaxis for lymphoma patients was the 
SIGNIFICANT trial, reported in 2005, on the use of levofloxacin in patients receiving CT 137. In 1565 
patients included in the study, the risk of fever, probable infections, the incidence of severe 
infections and hospitalization were all reduced in group treated with levofloxacin compared to one 
with placebo. However, there was no difference in infection-related deaths between the two 
groups 137. 
In 2012, a meta-analysis including trials which assessed patients with solid cancer or 
lymphoma, reported that quinolone antibiotics prophylaxis resulted in a significant decrease in 
febrile episodes, clinically documented infection, microbiologically documented infection, 
bacteremia and mortality rates. However, most trials in this meta-analysis included mainly high-risk 
hematological patients, with a smaller group of patients with lymphoma 138.  
In a recent retrospective analysis including exclusively lymphoma patients, there was no 
significant difference in the total incidence of infection episodes, FN or clinically documented 
infection, with antibiotic prophylaxis compared to patients without prophylaxis 139. The same result 
was found in the two subtypes of lymphoma of non-HL and HL. To our knowledge, this was the first 
study addressing only lymphoma patients on this topic. Altogether, it is assumed that there is no 
role for routine administration of prophylactic antibiotics with ABVD CT, and this recent study 
results support this conviction 136,139.  
Recently, an editorial in the New England Journal of Medicine, by Longo and colleagues, 
brings to discussion the progress in the treatment of HL in what it concerns the value of bleomycin 
as a component of ABVD regimen 140. The authors argue, based on several clinical studies, that 
bleomycin acute and chronic pulmonary toxicity may be the culprit for persistent decreased in 
overall survival in patients with HL that were not cured with the primary treatment approach 133,141-
144. It is also discussed how the incorporation of new active agents into frontline therapy, such as 
the anti-CD30 immunotoxin brentuximab-vedotin or the programmed death 1–inhibitor 
nivolumab, may be promising in the treatment for advanced stage HL 141,144. Other investigators 
randomly assigned patients to receive ABVD and patients to receive AVD plus brentuximab-vedotin 
(A+AVD) and found that progression-free survival rate was significantly increased in the A+AVD 
group 133. Neutropenia was higher in the A+AVD group, but successfully addressed by incorporating 
prophylaxis with G-CSF between doses. Mortality in the A+AVD group was attributed to treatment 
myelotoxicity, as compared ABVD group, which was associated with pulmonary toxicity. In ABVD 
treatment although neutropenia is frequent (38%), FN rate is only of 8% and does not justify 
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treatment alterations 133. In A+AVD, by probable contribution of brentuximab-vedotin, there are 
higher rates of both neutropenia and FN, which justifies prophylatic G-CSF 140. It would be 
interesting to further investigate why ABVD-induced neutropenia is less susceptible to infection 
than A+AVD. Moreover, the perception that neutropenia justifies ABVD treatment modifications, 
such as dose reductions or treatment delays, is not demonstrated in current literature.  
Despite treatment advances in younger patients with HL, the treatment of elderly HL 
patients , which constitute 20-30% of all patients diagnosed with HL, remains challenging 145.  
 Improvement in outcomes in elderly patients have not occurred at the same rate as in 
younger patients 146. It is known that elderly HL patients have a biologically more aggressive disease 
that might not respond well to treatment 147. Unlike younger patients, elderly HL patients 
experience higher rates of treatment toxicity and more frequently have early relapses 148. The 
inferior outcome in this older-aged group depends on the presence of co-morbidities, which 
decrease tolerance to CT and predispose to serious toxicity 149. In addition, myelosuppression 
increases with age and risk of neutropenia is increased in elderly patients receiving CT which may 
cause physicians to abstain from treatment and thus preclude the possibility of cure 150.   
The substantial contribution of age to therapeutic outcomes is such that several studies 
have investigated the effects of CT in the elderly population with HL 122,151. Management of 
neutropenia have specific recommendations regarding the elderly population 35,150.  
The CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) regimen was 
applied in advanced stage elderly patients, and although found to be effective in a small number of 
patients, FN was the most common toxicity (31%), but only limited conclusions on efficacy and 
toxicity can be drawn because of the small number of patients in this trial 148.  
In a study comparing efficacy and tolerability of ABVD and Stanford V in older HL patients, 
the rate of severe neutropenia in patients treated with ABVD or the Stanford V regimen 
(doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) 
was 64% in those older than 60 years and 38% in younger patients 152. No other significant 
differences in hematological or non-hematological adverse events were seen between the two CT 
regimens for older HL patients.  
The trial combining A+AVD in patients with advanced stage HL 133 included elderly patients 
up to 83 years of age and A+AVD resulted in more hospitalizations and higher toxicity compared 
with ABVD. Older patients were particularly prone to FN (37%), in line with previous reports 
suggesting that increased treatment intensity results in increased toxicity in older patients. In 
addition to the risk of infection and fever in elderly HL patients, neutropenia can also increase the 
risk for hospitalizations and contribute to nosocomial infection-associated mortality 13.  
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Importantly, most of the studies mentioned above are do not mention consistently how 
infection documentation was performed, if there was isolation of any infectious-agent in 
microbiology specimens and even if there has been any imagological documentation for pneumonia 
or infection. 
 
5.2. Neutropenia and Neutropenic Complications in Acute Myeloid Leukemia 
Treatment 
Bacterial and fungal infections are one of the major causes of morbidity and mortality in 
patients with AML during induction CT 153. They may cause not only an increased risk of death, but 
also an increased risk of leukemia relapse due to CT delays 154.  
Treatment for AML is classically divided into remission induction and post-remission 
consolidation therapy. Standard remission induction regimens include 3 days of infusional 
anthracycline and 7 days of cytarabine, commonly known as the “3+7” regimen 88. This therapeutic 
strategy for AML treatment has not changed significantly in more than 30 years 155,156. The question 
of whether intensification of the anthracycline dose, for remission induction therapy, might 
improve survival in patients with AML was addressed by a phase 3 randomized study conducted by 
Eastern Cooperative Oncology Group (ECOG) 157. Standard anthracycline dose (45 mg/m2 of body-
surface area) was compared with two times the same dose (90 mg/m2 of body-surface area), 
resulting in a higher rate of complete remission and improved overall survival in the high-dose 
anthracycline treated group. The rate of serious adverse events was similar between the two 
groups, namely, neutropenia, infection and FN 157.   
Hematopoietic growth factors are an optional adjunct to intensive induction therapy 88. 
However, evidence on their role in reducing the incidence or severity of infectious complications 
during bone marrow aplasia, and on their benefit through priming of leukemic cells to increase 
sensitivity to cytostatic agents, is not consensual 155,158-163. 
Remission induction regimen is an intensive cytotoxic therapy that can cause severe, 
prolonged or profound neutropenia with serious life-threatening infections, requiring the use of 
prophylactic antibacterial, antiviral, and antifungal agents in high-risk AML patients 21,164,165. 
Antimicrobial prophylaxis during remission induction CT in AML is a recommended starting point 
for managing these patients and relies on risk stratification according to clinical signs and 
symptoms, anticipated duration of neutropenia, and comorbidities 21,166,167. Whether this approach 
should be applied to all leukemic patients who receive induction CT has been a subject of 
controversy. Several clinical trials have shown that fluoroquinolone prophylaxis decreases 
infection-related all-cause mortality and morbidity and reduces the risk for all-cause clinically 
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documented and microbiologically documented bacterial infections in adult patients with AML who 
receive remission induction CT 31,138,166,168,169. However, the emergence of antimicrobial resistance 
associated with continuous use of fluoroquinolone prophylaxis, reduces both prophylaxis and 
treatment efficacy in neutropenic patients 21,170. Considering the risks and benefits, international 
guidelines suggest consideration of fluoroquinolone prophylaxis for neutropenic patients receiving 
induction CT for AML at high risk for profound prolonged neutropenia 24,35,171. Very high-risk AML 
patients are those with refractory or relapsed disease, previously submitted to several CT regimens 
and HSCT recipients 21,88. 
In order to reduce selective pressure for antimicrobial resistance and drug-drug 
interactions with antineoplastic agents, it has been recommended initiating prophylaxis after 
completion of CT, although, the optimal timing for initiating and discontinuing antibacterial 
prophylaxis as the duration of appropriate prophylactic treatment, have not been determined 171.  
Once hematological remission has been achieved, further consolidation therapy in AML 
treatment is required to prevent relapse. Options include repeated courses of consolidation CT 
followed by allogeneic HSCT for patients with intermediate and high-risk disease 88,172. Although 
HSCT is the only curative treatment for high-risk AML, the lack of an appropriate Human Leukocyte 
Antigen (HLA) donor and advanced age and comorbidities turn many patients ineligible for this 
strategy 173,174. 
Recent concerns regarding antimicrobial prophylaxis include increased risk of Clostridium 
difficile colitis, antimicrobial toxicities, and the potential for fostering multidrug-resistant 
pathogens. These emerging concerns coupled with the relatively shorter duration of neutropenia 
for AML patients with consolidative CT raise the question whether antimicrobial prophylaxis in this 
setting is necessary. A retrospective study was performed in patients who received high dose 
cytarabine consolidation therapy (HiDAC) 175. The primary endpoint of this study was the incidence 
of FN, while secondary endpoints consisted of hospitalizations for any cause as well as incidence of 
bacteremia, invasive fungal infection, Clostridium difficile colitis, and death from infection. 
Antimicrobial prophylaxis during consolidation CT with HiDAC did not reduce the incidence of FN 
frequency or hospitalizations. Additionally, there was no difference in the rates of bacteremia, 
Clostridium difficile colitis, or invasive fungal infections between the two groups. AML prophylactic 
antimicrobials may not be necessary for all patients consolidated with HiDAC due to a potentially 
shorter course of neutropenia when compared to patients with AML undergoing induction CT, 
especially younger AML patients 175.  
Development of immunotherapeutic agents and molecular targeted therapies have 
changed the antineoplastic therapy in hematology, with impact on both innate and adaptive 
immunity. Recent efforts have focused on adding therapies targeting molecular mutations to 
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traditional induction therapy, such as FLT3 inhibitors, kinase inhibitors, and agents blocking 
overexpressing multidrug resistance genes 172,176. Combination of intensively pretreated patients 
with different treatment modalities may be associated with potentially serious infections 177.  
As autoimmune inflammatory reactions are typical adverse events occurring in several of 
these patients, immunosuppressive treatment will often be required, that can cause secondary 
infections. Therefore, differential diagnostic efforts are important to distinguish inflammatory 
reactions from infections and recommendations for routine antimicrobial prophylaxis should be 
avoided 178-182.  
Abnormal DNA methylation plays a critical role in the impairment of differentiation of 
myeloid cells in AML 183,184. With the breakthrough of molecular biology research on the 
characteristics and pathogenesis of AML, hypomethylating agents (HMA) have become beneficial 
for its treatment. Two HMA, azacitidine and decitabine, have been approved by the USA Food and 
Drug Administration (FDA) for treating AML, and previous clinical trials have shown that the efficacy 
of demethylation therapy is superior to conventional care regimens 185-191. Decitabine as a reduced-
intensity therapy for older or unfit patients with AML, has few precise data available on the 
incidence and characteristics of bacterial, fungal, and viral infections in AML 41,192. The risk of 
infection with decitabine treatment was addressed in a recent retrospective study, where infection-
related serious adverse events were identified in AML 193. In patients receiving 10-day cycles of 
decitabine infectious complications were common (30%) and may occur during any cycle of 
therapy. Although frequently culture-negative, febrile events in decitabine treatment are more 
often associated with infections caused by Gram-positive bacteria, while those caused by Gram-
negative bacteria represent a significant risk of mortality 193. High concentrations of decitabine 
inhibit DNA synthesis and induce cell death, and their clinical application is largely limited by its 
inherent cytotoxicity. Nevertheless, low-dose of decitabine has the demethylation effect rather 
than cytotoxic effect, which makes it feasible to reduce myelosuppression by decreasing the dosage 
194,195. Kantarjian and colleagues found that serious adverse events were experienced by nearly 70% 
of decitabine patients due to myelosuppression-related side effects 187. Similarly, another study 
showed that FN was present in 25% of patients receiving decitabine compared with 7% of patients 
receiving best supportive care 189. 
In clinical practice, bone marrow suppression is the most common adverse reaction in 
demethylation therapy and the main reason for the dose-reduction or discontinuations of this 
therapeutic regimen. Therefore, the purpose of a recent meta-analysis was to fully assess the 
incidence and relative risk of the hematologic toxicity effects associated with HMA 196. For the 
analysis of high-grade hematologic toxicity effects, the incidence of anemia, neutropenia, 
thrombocytopenia, and FN was 27%, 45%, 38%, and 25%, respectively. This meta-analysis also 
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demonstrated that the relative risk of high-grade anemia, leukopenia, and FN in comparison with 
conventional care regimens did not significantly increase among patients receiving HMA 196. These 
findings can provide strong evidence for clinicians when assessing the risk-benefit balance of HMA 
in clinical practice. 
 
5.2.1.  Invasive Fungal Disease  
Patients with AML treated with myelosuppressive CT, like cytarabine and anthracycline, are 
in risk for developing IFD, namely due to prolonged and profound neutropenia and monocytopenia, 
use of purine analogues (fludarabine), the presence of indwelling intravenous catheters, 
gastrointestinal mucositis and individual genetic predispositions 197.
 
Additionally, pre-admission 
factors in AML patients may increase IFD risk, like Chronic Obstructive Pulmonary Disease (COPD), 
professional exposure to fungal pathogens, influenza H1N1 infection and a lack of response to 
remission induction CT 198,199.
 
Fungal infections occur in 5% to 40% of patients with hematologic 
malignancies and are most common in AML 200.  
With the increasing use of intensive immunosuppressive cancer therapies, IFD became 
more frequent and is a leading cause of morbidity and mortality, also attributed to the diagnostic 
difficulties of fungal infection and delayed treatment initiation. Limited activity of antifungal agents, 
their side effects, and increasing use of corticosteroids, further facilitates fungal dissemination 201. 
Aspergillus and Candida species (spp) currently account for 95% of all cases, but the 
epidemiological characteristics of IFD evolve under the selection pressure of antimicrobials and 
other factors 202,203. Aspergillus	has become the dominant species in Europe with the incidence of 
invasive aspergillosis in AML ranging from 5% to 24%, while rates of candidaemia are 2% 204.
 
In a 
multicenter study, the overall rate of proven and probable aspergillosis in patients with AML 
receiving remission induction CT was 8.1% 205. Although significant variation in the incidence rate 
was noted between participating centers, preventative measures such as a primary antifungal 
chemoprophylaxis has been recommended, but not all treating centers adopt it 205-208. 
Epidemiological surveys have reported much lower incidences (0%–5%) of IFD during consolidation 
CT than has been reported during the remission induction phase, though the intensity of 
consolidation regimen may impact on this risk 209. In general, primary antifungal prophylaxis is not 
recommended beyond remission induction CT, unless patients are to undergo re-induction CT or 
intensified consolidation therapy 206.  
Diagnosis of IFD is challenging and hampered by the relatively low sensitivity and specificity 
of the standard diagnostic procedures, as well as a low yield of the microbiological and 
histopathological tests 210-212. In the absence of a known pathogen, surrogate markers for IFD such 
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as persistent fever, computed tomography, fungal polymerase chain reaction, or serological assays, 
and local epidemiological data should guide treatment decisions 213.  
The most frequent mortality etiologies of acute respiratory failure (ARF) in hematological 
malignancies are bacterial infections, viral or opportunistic infections, followed by disease-related 
infiltrates and cardiogenic pulmonary edema 214. Regarding AML, recent studies described autopsy 
findings concerning the cause of death and lung pathology in patients with ARF between 2003 and 
2018 215. The study showed that in more than 50% of cases, major clinical diagnoses were missed. 
Lung malignant infiltration was frequently found (20%) accounting for most of the causes of death. 
Bacterial pneumonias and less often fungal pneumonias (10%) were also observed, proven to be 
less frequent than what has been previously described (24%) 204. However in about a third of cases 
of ARF without identified cause, pulmonary edema or alveolar damage were the only findings. 
Fungal infections reported in this study have shown that patients with ARF and fungal pneumonia 
were not receiving antifungals at the time of death 215.  
Primary antifungal prophylaxis during curative-intent therapy for AML has been 
continuously reviewed. Considering that no single agent will prevent all IFD, careful monitoring 
during the period of risk is essential with treatment of emergent fungal infections. Although 
prevention of IFD during neutropenia in AML induction therapy reduces morbidity and mortality, 
and shortens hospital stay, special considerations should be taken like considering drug toxicities, 
selection for resistant pathogens, adverse drug-drug interactions, and costs 200,203,206,216-218.  
Despite recent advances in the field of hematologic malignancies, such as non-invasive bio- 
markers for early diagnosis, radiographic screening and the widespread use of novel antifungal 
drugs, IFD remains a major cause of morbidity and mortality in patients with AML 219. 
 
5.3. Final Considerations 
 AML is an acute, rapidly evolving, and potentially fatal disease, whose prompt treatment 
with standard “3+7” CT regimen (anthracycline, cytarabine), is the only option to offer to these 
patients in the hope to achieve remission. This treatment has a well-recognized associated toxicity, 
with high incidence of FN. The potential risk of fatal infection associated with AML induction CT is, 
however, justified given the high risk of mortality associated with loss of disease control. Having 
AML as the FN paradigm, HL appears in this review as an example of a more indolent disease, 
presenting mostly in young patients, with a high cure rate when treated with ABVD combination 
CT. As mentioned above, ABVD is associated with high rates of severe neutropenia, but with a less 
clear subsequent associated infectious risk. The high neutropenia risk associated with ABVD may 
be related with both treatment delay and dose reduction which can compromise treatment efficacy 
in a disease with high curative intent. Some relevant aspects for the understanding of infection risk 
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in HL patients treated with ABVD, such as grade of neutropenia, duration of severe neutropenia 
and patient's age, are not well characterized in the literature. In fact, data from HL clinical studies 
demonstrate the difficulties in obtaining a thorough evaluation of neutropenia risk in some CT 
regimens, due to inconsistencies in reporting and documenting severe neutropenia, FN and febrile 
infection (neutropenic or non-neutropenic) 117,121,220. This lack of uniform information is particularly 
important in ABVD CT regimens considering the urgent need to withdraw conclusions in how to 
weight the timing of a high-curative CT regiment and its proven infection risk in HL. 
With this study we want to emphasize and bring to reflection the hypothesis of how HL 
patients may be having an overdefensive clinical approach, with CT dose reductions and delays in 
the presence of neutropenia, that in turn can compromise the cure of HL. Having AML CT-induced 
neutropenia and infectious risk as paradigm, and yet, not so solid and robust evidence for HL 
treatment-induced FN, the risk of infection in ABVD CT may be clinically overestimated.  
 
6. CONCLUSIONS 
FN is a medical emergency with high mortality without an appropriate treatment. It is 
imperative to assess the risk for serious complications in neutropenic patients to decide the use of 
prophylaxis and an antimicrobial therapy and the need for inpatient admission. High-risk patients 
with FN are those who are expected to be neutropenic (ANC <500 cells/µL) for more than 7 days 
and those with comorbidities. Those patients should be admitted. 
 An important advance in the management of FN has been the stratification of the patients 
with FN for the risk of complications and death, using validated predictive instruments, such as the 
MASCC score to identify low-risk patients who can benefit from simplified and less expensive 
therapeutic approaches. Although the MASCC scoring index has been widely accepted, there is still 
room for improving its effectiveness, especially for FN in patients with hematological malignancies 
25.  
 AML is an acute disease with a high mortality rate. Although its treatment is associated with 
severe risk of FN and infections, the risk and benefit evaluation favor a prompt initiation of the CT 
treatment and FN prophylaxis for a better survival of these patients. Moreover, since AML-treated 
patients are expected to have prolonged severe neutropenia, in this context, IFD should be 
prevented with antifungal prophylaxis in remission induction CT. Early diagnosis and appropriate 
treatment of serious infections in neutropenic patients is important, although lack of accurate 
clinical and microbiological data in these patients constitute major problems in the diagnostic 
approach. 
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 HL is a more indolent disease and commonly treated with neutropenia inducingCT 
regimens, such as ABVD, with a curative rate >80%. Therefore, therapeutic intervention with CT 
should not be compromised with dose delays or dose reductions in ABVD treatment. Although 
there are no well-designed studies addressing the risk of infection in CIN in HL, the studies 
demonstrate that CT dose delays or dose reductions with ABVD are not recommended only on a 
basis of ANC, contrarily to the majority of CT treatment regimens. Treatment modification are 
required in A+AVD, considering its high FN association and G-CSF prophylaxis, and in bleomycin 
containing regimens, especially due to its acute and sometimes lethal, pulmonary toxicity, and not 
due to infection in particular. 
Although not universally used, it appears that the greatest benefit of BEACOPP CT in the 
progression-free survival is among the highest-risk patients. However, this comes at the cost of 
increased toxicity with no clear improvement in patients overall-survival when compared with 
ABVD alone. Moreover, BEACOPP is associated with significantly more severe hematologic toxicity, 
infections, and occurrence of myelodysplastic syndrome and AML 120,121. 
Prophylactic measures have been shown to be effective in CT-induced FN. Unfortunately, 
the balance between their cost and wide benefit in FN management led to restrictive algorithms 
and guidelines for their use. It is highly desirable that future research focuses on the definition of 
subset of patients who could benefit from FN prophylaxis, taking into account the type of CT 
regimen, patient clinical and laboratorial stability and also comorbid conditions 25. 
Efforts in developing a more accurate and individualized approach in FN diagnosis and 
treatment should upraise against the development of microbial resistance, secondary infections, 
increased toxicity and hospitalization costs. To this end, each center should closely monitor its own 
causes of infection, antibiotic protocols and disease-specific CIN risk of infection 221. Susceptibility 
to infection in CIN could also profit on better understanding neutropenia daily evolution and 
characterizing, both morphological and functionally, the remaining neutrophils in these patients. 
As ECIL recently reviewed, a good balance between scientific rigor and clinical pragmatism 
reflects that guidelines are intended to deal with commonly anticipated risks to patient populations 
rather than being a recipe suited to each individual case 206. 
  
 23 
7. REFERENCES 
1. Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile 
neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol 
2012;23:1889-93. 
2. Moores KG. Safe and effective outpatient treatment of adults with chemotherapy-induced 
neutropenic fever. Am J Health Syst Pharm 2007;64:717-22. 
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating 
leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40. 
4. Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am J Med 
1986;80:13-20. 
5. Hartel C, Deuster M, Lehrnbecher T, Schultz C. Current approaches for risk stratification of 
infectious complications in pediatric oncology. Pediatr Blood Cancer 2007;49:767-73. 
6. Wicki S, Keisker A, Aebi C, Leibundgut K, Hirt A, Ammann RA. Risk prediction of fever in 
neutropenia in children with cancer: a step towards individually tailored supportive therapy? 
Pediatr Blood Cancer 2008;51:778-83. 
7. Pandya PH, Murray ME, Pollok KE, Renbarger JL. The Immune System in Cancer 
Pathogenesis: Potential Therapeutic Approaches. J Immunol Res 2016;2016:4273943. 
8. Wardill HR, Bowen JM. Chemotherapy-induced mucosal barrier dysfunction: an updated 
review on the role of intestinal tight junctions. Curr Opin Support Palliat Care 2013;7:155-61. 
9. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile 
neutropenia during cancer therapy. N Engl J Med 2013;368:1131-9. 
10. Culakova E, Thota R, Poniewierski MS, et al. Patterns of chemotherapy-associated toxicity 
and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med 
2014;3:434-44. 
11. Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG. Risk and consequences of 
chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the 
importance of duration of prophylaxis. BMC Health Serv Res 2014;14:189. 
12. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost 
associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66. 
13. Dulisse B, Li X, Gayle JA, et al. A retrospective study of the clinical and economic burden 
during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013;16:720-
35. 
14. Michels SL, Barron RL, Reynolds MW, Smoyer Tomic K, Yu J, Lyman GH. Costs associated 
with febrile neutropenia in the US. Pharmacoeconomics 2012;30:809-23. 
15. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, 
and new directions for its management. Cancer 2004;100:228-37. 
16. Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer 
chemotherapy. J Oncol Pract 2010;6:149-52. 
17. Lyman GH, Dale DC, Culakova E, et al. The impact of the granulocyte colony-stimulating 
factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis 
of randomized controlled trials. Ann Oncol 2013;24:2475-84. 
18. Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes 
in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221-
40. 
19. Klastersky J. Management of fever in neutropenic patients with different risks of 
complications. Clin Infect Dis 2004;39 Suppl 1:S32-7. 
20. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or 
septic shock. Crit Care Med 2012;40:43-9. 
21. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of 
antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases 
Society of America. Clin Infect Dis 2011;52:427-31. 
 24 
22. Malik I, Hussain M, Yousuf H. Clinical characteristics and therapeutic outcome of patients 
with febrile neutropenia who present in shock: need for better strategies. J Infect 2001;42:120-5. 
23. Wunderlich CA, Seguin E. Medical thermometry and human temperature. New York: New 
York : Wood, 1871; 1871. 
24. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO 
Clinical Practice Guidelines. Annals of Oncology 2016;27 v111–v8. 
25. Klastersky J, Paesmans M, Aoun M, et al. Clinical research in febrile neutropenia in cancer 
patients: Past achievements and perspectives for the future. World J Clin Infect Dis 2016;25:37-60  
26. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of 
fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J 
Med 1991;325:164-70. 
27. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim 
prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-
controlled phase III study. J Clin Oncol 2005;23:1178-84. 
28. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with 
granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients 
receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67. 
29. Bow EJ. Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute 
leukemia and myelodysplastic syndromes. Semin Hematol 2009;46:259-68. 
30. Society. IH. The design, analysis, and reporting of clinical trials on the empirical antibiotic 
management of the neutropenic patient. Report of a consensus panel. Journal of Infectious 
Diseases 1990;161:397-401. 
31. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient 
management of fever and neutropenia in adults treated for malignancy: American Society of 
Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:794-810. 
32. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced 
neutropenia. Oncologist 2005;10:427-37. 
33. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired 
chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 
2006;14:901-9. 
34. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use 
of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 
2006;24:3187-205. 
35. Baden LR, Swaminathan S, Angarone M, al. e. Prevention and Treatment of Cancer-Related 
Infections. National Comprehensive Cancer Network (NCCN Guidelines®) - Clinical Practice 
Guidelines in Oncology 2018;Version 1.2018. 
36. Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious 
complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index 
of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 
2015;33:465-71. 
37. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for 
Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile 
neutropenic cancer patients. J Clin Oncol 2000;18:3038-51. 
38. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever 
and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 
1992;10:316-22. 
39. Aguilar-Guisado M, Espigado I, Martin-Pena A, et al. Optimisation of empirical antimicrobial 
therapy in patients with haematological malignancies and febrile neutropenia (How Long study): 
an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017;4:e573-e83. 
40. Blot F, Nitenberg G. [High and low-risk febrile neutropenic patients]. Presse Med 
2004;33:467-73. 
 25 
41. Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic 
prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res 2011;35:499-
503. 
42. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. 
Int J Antimicrob Agents 2007;30 Suppl 1:S51-9. 
43. Nesher L, Rolston KV. The current spectrum of infection in cancer patients with 
chemotherapy related neutropenia. Infection 2014;42:5-13. 
44. Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia 
in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases 
Society of America Clinical Practice Guideline Update. J Clin Oncol 2018;36:1443-53. 
45. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating 
factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-
analysis. BMC Cancer 2011;11:404. 
46. Zimmer AJ, Freifeld AG. Optimal Management of Neutropenic Fever in Patients With 
Cancer. J Oncol Pract 2019;15:19-24. 
47. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and 
gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5. 
48. Schimpff SC. Gram-negative bacteremia. Support Care Cancer 1993;1:5-18. 
49. Teuffel O, Ethier MC, Alibhai SM, Beyene J, Sung L. Outpatient management of cancer 
patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 2011;22:2358-
65. 
50. Moghnieh R, Estaitieh N, Mugharbil A, et al. Third generation cephalosporin resistant 
Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile 
neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, 
and correlation with poor prognosis. Front Cell Infect Microbiol 2015;5:11. 
51. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked 
diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol 
2008;26:5684-8. 
52. Cho SY, Choi HY. Opportunistic fungal infection among cancer patients. A ten-year autopsy 
study. Am J Clin Pathol 1979;72:617-21. 
53. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces 
mortality in neutropenic patients. Ann Intern Med 2005;142:979-95. 
54. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for 
chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin 
Oncol 2005;23:4198-214. 
55. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of 
granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile 
neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 
2011;47:8-32. 
56. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of 
prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann 
Intern Med 2007;147:400-11. 
57. Mitchell S, Li X, Woods M, et al. Comparative effectiveness of granulocyte colony-
stimulating factors to prevent febrile neutropenia and related complications in cancer patients in 
clinical practice: A systematic review. J Oncol Pharm Pract 2016;22:702-16. 
58. Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with 
granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic 
review and meta-analysis of randomized controlled trials. Support Care Cancer 2015;23:3131-40. 
59. Cornely OA, Wicke T, Seifert H, et al. Once-daily oral levofloxacin monotherapy versus 
piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients 
with febrile neutropenia. Int J Hematol 2004;79:74-8. 
 26 
60. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on 
mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014;58:3799-803. 
61. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial 
therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th 
European Conference on Infections in Leukemia. Haematologica 2013;98:1826-35. 
62. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent 
fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin 
Infect Dis 2003;37:382-9. 
63. Group EOfRaToCEIATCGatNCIoC-CT. Vancomycin added to empirical combination 
antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8. 
64. See I, Iwamoto M, Allen-Bridson K, Horan T, Magill SS, Thompson ND. Mucosal barrier injury 
laboratory-confirmed bloodstream infection: results from a field test of a new National Healthcare 
Safety Network definition. Infect Control Hosp Epidemiol 2013;34:769-76. 
65. Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-glucan, 
Aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage 
fluid for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2014;52:2039-45. 
66. Sulahian A, Porcher R, Bergeron A, et al. Use and limits of (1-3)-beta-d-glucan assay 
(Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of 
invasive aspergillosis. J Clin Microbiol 2014;52:2328-33. 
67. Theel ES, Doern CD. beta-D-glucan testing is important for diagnosis of invasive fungal 
infections. J Clin Microbiol 2013;51:3478-83. 
68. Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv19-iv29. 
69. Glaser SL, Jarrett RF. The epidemiology of Hodgkin's disease. Baillieres Clin Haematol 
1996;9:401-16. 
70. Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J. Epstein-Barr viral DNA in tissues of 
Hodgkin's disease. Am J Pathol 1987;129:86-91. 
71. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-
Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000;82:1117-21. 
72. Franceschi S, Dal Maso L, La Vecchia C. Advances in the epidemiology of HIV-associated 
non-Hodgkin's lymphoma and other lymphoid neoplasms. Int J Cancer 1999;83:481-5. 
73. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after 
infectious mononucleosis. N Engl J Med 2003;349:1324-32. 
74. Andrieu JM, Roithmann S, Tourani JM, et al. Hodgkin's disease during HIV1 infection: the 
French registry experience. French Registry of HIV-associated Tumors. Ann Oncol 1993;4:635-41. 
75. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus 
infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative 
Group on AIDS and Tumors. J Clin Oncol 1995;13:1758-67. 
76. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and 
management. Am J Hematol 2018;93:704-15. 
77. Mauch PM, Kalish LA, Kadin M, Coleman CN, Osteen R, Hellman S. Patterns of presentation 
of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 1993;71:2062-71. 
78. Gobbi PG, Cavalli C, Gendarini A, et al. Reevaluation of prognostic significance of symptoms 
in Hodgkin's disease. Cancer 1985;56:2874-80. 
79. Townsend W, Linch D. Hodgkin's lymphoma in adults. Lancet 2012;380:836-47. 
80. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA 
Cancer J Clin 2018;68:116-32. 
81. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in 
Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) 
germinal center B cells. J Exp Med 1996;184:1495-505. 
82. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an 
expansion of a single clone originating from a germinal center B-cell with functional 
 27 
immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 
2000;95:1443-50. 
83. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood 2016;127:2375-90. 
84. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 
18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's 
disease. Haematologica 2001;86:266-73. 
85. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, 
and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin 
Oncol 2014;32:3059-68. 
86. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response 
assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas 
Imaging Working Group. J Clin Oncol 2014;32:3048-58. 
87. Cancer stat facts: leukemia—acute myeloid leukemia (AML). 2017. 2019, at 
https://seer.cancer.gov/statfacts/html/amyl.html.) 
88. Fey MF, Buske C, Group EGW. Acute myeloblastic leukaemias in adult patients: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 
6:vi138-43. 
89. Short NJ, Rytting ME, Cortes JE. Acute Myeloid Leukemia. The Lancet 2018;392:593-606. 
90. Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014;383:2239-52. 
91. Tefferi A, Pardanani A. Myeloproliferative Neoplasms: A Contemporary Review. JAMA 
Oncol 2015;1:97-105. 
92. Zuckerman T, Ganzel C, Tallman MS, Rowe JM. How I treat hematologic emergencies in 
adults with acute leukemia. Blood 2012;120:1993-2002. 
93. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling 
in acute myeloid leukemia. N Engl J Med 2012;366:1079-89. 
94. Bullinger L, Dohner K, Dohner H. Genomics of Acute Myeloid Leukemia Diagnosis and 
Pathways. J Clin Oncol 2017;35:934-46. 
95. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in 
Acute Myeloid Leukemia. N Engl J Med 2016;374:2209-21. 
96. Shafer D, Grant S. Update on rational targeted therapy in AML. Blood Rev 2016;30:275-83. 
97. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization 
classification of myeloid neoplasms and acute leukemia. Blood 2016;127:2391-405. 
98. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management 
of acute leukemia. Arch Pathol Lab Med 2011;135:44-54. 
99. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 
ELN recommendations from an international expert panel. Blood 2017;129:424-47. 
100. Dizon DS, Krilov L, Cohen E, et al. Clinical Cancer Advances 2016: Annual Report on Progress 
Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2016;34:987-1011. 
101. Li J, Smith A, Crouch S, Oliver S, Roman E. Estimating the prevalence of hematological 
malignancies and precursor conditions using data from Haematological Malignancy Research 
Network (HMRN). Cancer Causes Control 2016;27:1019-26. 
102. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, 
oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102. 
103. Bruno B, Busca A, Vallero S, et al. Current use and potential role of procalcitonin in the 
diagnostic work up and follow up of febrile neutropenia in hematological patients. Expert Rev 
Hematol 2017;10:543-50. 
104. Toussaint E, Bahel-Ball E, Vekemans M, et al. Causes of fever in cancer patients (prospective 
study over 477 episodes). Support Care Cancer 2006;14:763-9. 
105. Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care 
Cancer 2005;13:870-7. 
106. Hilson AJ. Pel-Ebstein fever. N Engl J Med 1995;333:66-7. 
 28 
107. Bodey GP. The changing face of febrile neutropenia-from monotherapy to moulds to 
mucositis. Fever and neutropenia: the early years. J Antimicrob Chemother 2009;63 Suppl 1:i3-13. 
108. Liaw CC, Huang JS, Chen JS, Chang JW, Chang HK, Liau CT. Using vital sign flow sheets can 
help to identify neoplastic fever and other possible causes in oncology patients: a retrospective 
observational study. J Pain Symptom Manage 2010;40:256-65. 
109. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R. Clinical correlates of 
elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 
1997;102:21-8. 
110. Pasikhova Y, Ludlow S, Baluch A. Fever in Patients With Cancer. Cancer Control 
2017;24:193-7. 
111. Rusu RA, Sirbu D, Curseu D, et al. Chemotherapy-related infectious complications in 
patients with Hematologic malignancies. J Res Med Sci 2018;23:68. 
112. Donadieu J, Fenneteau O, Beaupain B, Mahlaoui N, Chantelot CB. Congenital neutropenia: 
diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011;6:26. 
113. Diehl V, Sieber M, Ruffer U, et al. BEACOPP: an intensified chemotherapy regimen in 
advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 
1997;8:143-8. 
114. Hasenclever D, Loeffler M, Diehl V. Rationale for dose escalation of first line conventional 
chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann 
Oncol 1996;7 Suppl 4:95-8. 
115. Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for 
advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998;9 
Suppl 5:S73-8. 
116. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including 
escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or 
advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011:CD007941. 
117. Carde P, Karrasch M, Fortpied C, et al. Eight Cycles of ABVD Versus Four Cycles of 
BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic 
Score >/= 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup 
Trial. J Clin Oncol 2016;34:2028-36. 
118. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP 
chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 
2003;348:2386-95. 
119. Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and 
practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. 
German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000;11:1105-14. 
120. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with 
CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the 
HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-11. 
121. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma 
when high-dose salvage is planned. N Engl J Med 2011;365:203-12. 
122. Ballova V, Ruffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by 
the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease 
comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-31. 
123. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV 
hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 
2003;21:607-14. 
124. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and 
future. Nat Clin Pract Oncol 2008;5:543-56. 
125. Raemaekers JM, van der Maazen RW. Hodgkin's lymphoma: news from an old disease. Neth 
J Med 2008;66:457-66. 
 29 
126. Chand VK, Link BK, Ritchie JM, Shannon M, Wooldridge JE. Neutropenia and febrile 
neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), 
bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. Leuk Lymphoma 2006;47:657-63. 
127. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose 
reductions or growth factors. Ann Oncol 2007;18:376-80. 
128. Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity 
with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-
year analysis. Br J Haematol 2007;137:545-52. 
129. Nangalia J, Smith H, Wimperis JZ. Isolated neutropenia during ABVD chemotherapy for 
Hodgkin lymphoma does not require growth factor support. Leuk Lymphoma 2008;49:1530-6. 
130. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease 
with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-84. 
131. Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and alternating or hybrid 
multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United 
Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 2005;23:9208-18. 
132. Schwenkglenks M, Pettengell R, Szucs TD, Culakova E, Lyman GH. Hodgkin lymphoma 
treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy 
delivery. J Hematol Oncol 2010;3:27. 
133. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with Chemotherapy for Stage 
III or IV Hodgkin's Lymphoma. N Engl J Med 2018;378:331-44. 
134. Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V 
with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an 
intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 
2013;31:684-91. 
135. Russo F, Corazzelli G, Frigeri F, et al. A phase II study of dose-dense and dose-intense ABVD 
(ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. 
Br J Haematol 2014;166:118-29. 
136. Vakkalanka B, Link BK. Neutropenia and Neutropenic Complications in ABVD Chemotherapy 
for Hodgkin Lymphoma. Adv Hematol 2011;2011:656013. 
137. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for 
solid tumors and lymphomas. N Engl J Med 2005;353:988-98. 
138. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in 
afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 
2012;1:CD004386. 
139. Yildiz A, Ozturk HB, Albayrak M, et al. Is antimicrobial prophylaxis necessary for lymphoma 
patients? A single centre, real-life experience. J Oncol Pharm Pract 2018:1078155218795323. 
140. Longo DL, DeVita VT, Jr. Progress in the Treatment of Hodgkin's Lymphoma. N Engl J Med 
2018;378:392-4. 
141. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or 
refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311-9. 
142. Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from 
the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an 
open-label, randomised, non-inferiority trial. Lancet 2015;385:1418-27. 
143. Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT 
Scan in Advanced Hodgkin's Lymphoma. N Engl J Med 2016;374:2419-29. 
144. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-
positive lymphomas. N Engl J Med 2010;363:1812-21. 
145. Borchmann S, Engert A, Boll B. Hodgkin lymphoma in elderly patients. Curr Opin Oncol 
2018;30:308-16. 
146. Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-
based study on patients diagnosed in Sweden from 1973-2009. Blood 2012;119:990-6. 
 30 
147. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a 
comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 
2005;23:5052-60. 
148. Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H. Standard CHOP-21 as first 
line therapy for elderly patients with Hodgkin's lymphoma. Leuk Lymphoma 2007;48:570-6. 
149. van Spronsen DJ, Janssen-Heijnen ML, Lemmens VE, Peters WG, Coebergh JW. Independent 
prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven 
Cancer Registry. Eur J Cancer 2005;41:1051-7. 
150. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines 
for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003;39:2264-
72. 
151. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with 
classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary 
events suggest limiting the use of bleomycin in the elderly. Br J Haematol 2015;170:179-84. 
152. Evens AM, Hong F, Gordon LI, et al. The efficacy and tolerability of adriamycin, bleomycin, 
vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive 
analysis from the North American intergroup trial E2496. Br J Haematol 2013;161:76-86. 
153. Hamalainen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. Neutropenic 
fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive 
chemotherapy: Causes and consequences. Leuk Lymphoma 2008;49:495-501. 
154. Malagola M, Peli A, Damiani D, et al. Incidence of bacterial and fungal infections in newly 
diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens 
including fludarabine: retrospective analysis of 224 cases. Eur J Haematol 2008;81:354-63. 
155. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia 
in adults: recommendations from an international expert panel, on behalf of the European 
LeukemiaNet. Blood 2010;115:453-74. 
156. Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 
2015;373:1136-52. 
157. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid 
leukemia. N Engl J Med 2009;361:1249-59. 
158. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia 
who did not undergo transplantation in first remission. J Clin Oncol 2013;31:1293-301. 
159. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am 
J Hematol 2013;88:318-27. 
160. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-
stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 
2003;349:743-52. 
161. Pabst T, Vellenga E, van Putten W, et al. Favorable effect of priming with granulocyte 
colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose 
escalation of cytarabine. Blood 2012;119:5367-73. 
162. Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute 
myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2012;13:207-14. 
163. Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012;24:711-9. 
164. Hammond SP, Baden LR. Antibiotic prophylaxis during chemotherapy-induced neutropenia 
for patients with acute leukemia. Curr Hematol Malig Rep 2007;2:97-103. 
165. Ward TT, Thomas RG, Fye CL, et al. Trimethoprim-sulfamethoxazole prophylaxis in 
granulocytopenic patients with acute leukemia: evaluation of serum antibiotic levels in a 
randomized, double-blind, placebo-controlled Department of Veterans Affairs Cooperative Study. 
Clin Infect Dis 1993;17:323-32. 
166. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in 
patients with cancer and neutropenia. N Engl J Med 2005;353:977-87. 
 31 
167. Lech-Maranda E, Seweryn M, Giebel S, et al. Infectious complications in patients with acute 
myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or 
without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int 
J Infect Dis 2010;14:e132-40. 
168. Cullen M, Baijal S. Prevention of febrile neutropenia: use of prophylactic antibiotics. Br J 
Cancer 2009;101 Suppl 1:S11-4. 
169. Felsenstein S, Orgel E, Rushing T, Fu C, Hoffman JA. Clinical and microbiologic outcomes of 
quinolone prophylaxis in children with acute myeloid leukemia. Pediatr Infect Dis J 2015;34:e78-84. 
170. Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with 
chemotherapy-induced neutropenia. Curr Opin Hematol 2012;19:21-6. 
171. McCarthy MW, Walsh TJ. Prophylactic Measures During Induction for Acute Myeloid 
Leukemia. Curr Oncol Rep 2017;19:18. 
172. Smith BD, Stein EM. Acute myeloid leukemia 
American Society of Hematology Self-Assessment Program, Sixth Edition. In: Steensma DP, Cuker 
A, Kempton CL, Nowakowski GS, eds.2016. 
173. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009;113:6296-303. 
174. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147-56. 
175. Vale C, Farmakiotis D, Egan PC, Ingham R, Reagan JL. Outcomes Associated with 
Antimicrobial Use during High Dose Cytarabine Consolidation in Acute Myeloid Leukemia. Blood 
2018;132 no. Suppl 1 1402. 
176. Davis JR, Benjamin DJ, Jonas BA. New and emerging therapies for acute myeloid leukaemia. 
J Investig Med 2018;66:1088-95. 
177. Reinwald M, Silva JT, Mueller NJ, et al. ESCMID Study Group for Infections in Compromised 
Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an 
infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR 
inhibitors). Clin Microbiol Infect 2018;24 Suppl 2:S53-S70. 
178. Alflen A, Stadler N, Aranda Lopez P, et al. Idelalisib impairs TREM-1 mediated neutrophil 
inflammatory responses. Sci Rep 2018;8:5558. 
179. Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and 
pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous 
leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14:826-32. 
180. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune 
checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139-48. 
181. Roger T, Lugrin J, Le Roy D, et al. Histone deacetylase inhibitors impair innate immune 
responses to Toll-like receptor agonists and to infection. Blood 2011;117:1205-17. 
182. Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with 
immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper 
by the European Conference on Infections in Leukemia (ECIL). Leukemia 2019;33:844-62. 
183. Shen N, Yan F, Pang J, et al. Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA 
Methylation in Acute Myeloid Leukemia. Clin Cancer Res 2017;23:6254-66. 
184. Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute 
myeloid leukemia. Leukemia 2014;28:1-14. 
185. Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs 
conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 
2015;126:291-9. 
186. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that 
of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a 
randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32. 
187. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in 
myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803. 
188. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, 
phase III trial of decitabine versus patient choice, with physician advice, of either supportive care 
 32 
or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid 
leukemia. J Clin Oncol 2012;30:2670-7. 
189. Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly 
patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive 
chemotherapy: final results of the randomized phase III study of the European Organisation for 
Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 
2011;29:1987-96. 
190. Mawad R, Becker PS, Hendrie P, et al. Phase II study of tosedostat with cytarabine or 
decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. Br J 
Haematol 2016;172:238-45. 
191. Sanchez-Garcia J, Falantes J, Medina Perez A, et al. Prospective randomized trial of 5 days 
azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 
5q deletion and transfusion-dependent anemia. Leuk Lymphoma 2018;59:1095-104. 
192. Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. 
Haematologica 2012;97:1459-70. 
193. Ali AM, Weisel D, Gao F, et al. Patterns of infectious complications in acute myeloid 
leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer 
Med 2017;6:2814-21. 
194. Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol 2007;61:140-
52. 
195. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of 
low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic 
leukemia. Blood 2007;109:52-7. 
196. Gao C, Wang J, Li Y, et al. Incidence and risk of hematologic toxicities with hypomethylating 
agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic 
review and meta-analysis. Medicine (Baltimore) 2018;97:e11860. 
197. Lupiañez CB, Canet LM, Carvalho A, et al. Polymorphisms in Host Immunity-Modulating 
Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. Infection and 
Immunity 2015;14. 
198. Caira M, Candoni A, Verga L, et al. Pre-chemotherapy risk factors for invasive fungal 
diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia 
(SEIFEM 2010-a multicenter study). Haematologica 2015;100:284-92. 
199. Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V. Risk stratification for invasive 
aspergillosis in immunocompromised patients. Ann N Y Acad Sci 2012;1272:23-30. 
200. Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. Mixed treatment comparison 
of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for 
haematological malignancies: a systematic review. J Antimicrob Chemother 2014;69:1-11. 
201. Lewis RE, Cahyame-Zuniga L, Leventakos K, et al. Epidemiology and sites of involvement of 
invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. 
Mycoses 2013;56:638-45. 
202. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do 
we prevent and treat them? Clin Infect Dis 2010;50:405-15. 
203. Tacke D, Buchheidt D, Karthaus M, et al. Primary prophylaxis of invasive fungal infections 
in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious 
Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 
2014;93:1449-56. 
204. Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer 
Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and 
Treatment of Cancer (EORTC 65031). Clin Infect Dis 2015;61:324-31. 
205. Donnelly JP, Cordonnier C, Cuenca-Estrella M, et al. A European period-prevalence study to 
estimate the rate of invasive pulmonary mould disease (PIMDA study).  ECCMID 2014. Barcelona, 
Spain2014. 
 33 
206. Maertens JA, Girmenia C, Bruggemann RJ, et al. European guidelines for primary antifungal 
prophylaxis in adult haematology patients: summary of the updated recommendations from the 
European Conference on Infections in Leukaemia. J Antimicrob Chemother 2018;73:3221-30. 
207. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications 
among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow 
Transplant 2009;44:453-5. 
208. Yokoe D, Casper C, Dubberke E, et al. Infection prevention and control in health-care 
facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 
2009;44:495-507. 
209. Wang L, Hu J, Sun Y, et al. Does High-Dose Cytarabine Cause More Fungal Infection in 
Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, 
Prospective, Observational Study in China. Medicine (Baltimore) 2016;95. 
210. Tsitsikas DA, Morin A, Araf S, et al. Impact of the revised (2008) EORTC/MSG definitions for 
invasive fungal disease on the rates of diagnosis of invasive aspergillosis. Med Mycol 2012;50:538-
42. 
211. Luong ML, Clancy CJ, Vadnerkar A, et al. Comparison of an Aspergillus real-time polymerase 
chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis 
of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011;52:1218-26. 
212. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage 
fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic 
malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011;17:1043-50. 
213. Rothenbuhler C, Held U, Manz MG, Schanz U, Gerber B. Continuously infused amphotericin 
B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia. 
Hematol Oncol 2018;36:471-80. 
214. Azoulay E, Pickkers P, Soares M, et al. Acute hypoxemic respiratory failure in 
immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care 
Med 2017;43:1808-19. 
215. Van de Louw A, Lewis AM, Yang Z. Autopsy findings in patients with acute myeloid leukemia 
and non-Hodgkin lymphoma in the modern era: a focus on lung pathology and acute respiratory 
failure. Ann Hematol 2018. 
216. Halpern AB, Lyman GH, Walsh TJ, Kontoyiannis DP, Walter RB. Primary antifungal 
prophylaxis during curative-intent therapy for acute myeloid leukemia. Blood 2015;126:2790-7. 
217. Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in 
patients with haematological malignancies: 2017 update of the recommendations of the Infectious 
Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology 
(DGHO). Ann Hematol 2018;97:197-207. 
218. Tormo M, Perez-Martinez A, Calabuig M, et al. Primary prophylaxis of invasive fungal 
infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk 
myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world 
comparison. Mycoses 2018;61:206-12. 
219. Lien MY, Chou CH, Lin CC, et al. Epidemiology and risk factors for invasive fungal infections 
during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective 
cohort study. PLoS One 2018;13:e0197851. 
220. Fossa A, Fiskvik IH, Kolstad A, et al. Two escalated followed by six standard BEACOPP in 
advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic 
osteonecrosis. Ann Oncol 2012;23:1254-9. 
221. Calik S, Ari A, Bilgir O, et al. The relationship between mortality and microbiological 
parameters in febrile neutropenic patients with hematological malignancies. Saudi Med J 
2018;39:878-85. 
 
